TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors

Nagasaka, M; Ohe, Y; Zhou, CC; Choi, CM; Yang, N; Liu, G; Felip, E; Pérol, M; Besse, B; Nieva, J; Raez, L; Pennell, NA; Dimou, A; de Marinis, F; Ciardiello, F; Seto, T; Hu, ZY; Pan, M; Wang, WQ; Li, SL; Ou, SHI

Nagasaka, M; Ou, SHI (通讯作者)，Univ Calif Irvine, Sch Med, Orange, CA 92697 USA.;Nagasaka, M; Ou, SHI (通讯作者)，Chao Family Comprehens Canc Ctr, Orange, CA 92868 USA.

FUTURE ONCOLOGY, 2023; 19 (2): 123

Abstract

Crizotinib and entrectinib have been approved to treat ROS1 fusion-positive (ROS1(+)) non-small-cell lung cancer. However, unmet needs remain, includi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索